Home
- Lectures
- Biomedical Translation Research Center
- Location
C212 Lecture Room, National Biotechnology Research Park
- Speaker Name
Dr. J. Jean Cui (Scientific Founder, President, and CEO of BlossomHill Therapeutics, Inc.)
- State
Definitive
- Url
2024-07-22 10:30 - 11:30
We are honored to announce that Dr. J. Jean Cui, a National Academy of Engineering member, will visit BioTReC and deliver a lecture on “Understanding Protein Dynamics for Structure-based Drug Design: Design Stories of Crizotinib, Lorlatinib and Repotrectinib” in NBRP on July 22, 2024.
Dr. J. Jean Cui, a renowned oncology drug designer, invented three FDA-approved medicines. She co-founded BlossomHill Therapeutics, Inc., and was the Scientific Founder of Turning Point Therapeutics, Inc. (TP). TP, under her leadership, went public and was acquired for $4.1 billion. At Pfizer, she pioneered Crizotinib and Lorlatinib. Her innovations led to accolades like election to the National Academy of Engineering and the National Inventor of the Year Award in 2024, significantly advancing cancer treatment.
Join us to explore cutting-edge kinase drug design! Learn how Crizotinib, Lorlatinib, and Repotrectinib tackle cancer drug resistance through innovative protein dynamics insights.
Time: 10:30-11:30 am, Monday, July 22, 2024
Venue: Rm 212, Bldg. C, NBRP
Speaker: Dr. J. Jean Cui
Lecture Language: English
Registration: https://forms.gle/pbYuNUGCw8p1Uj7D8
Your participation and online registration are highly appreciated.
